Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

3.500 -0.060 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,221,825
Open 3.570
Bid (Size) 3.450 (1)
Ask (Size) 3.490 (55)
Prev. Close 3.560
Today's Range 3.455 - 3.640
52wk Range 2.280 - 8.807
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Adaptive Biotechnologies Topped the Market Today
A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares. 
Via The Motley Fool
ADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024
ADPT stock results show that Adaptive Biotechnologies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-26.62%
-26.62%
1 Month
+31.09%
+31.09%
3 Month
-7.41%
-7.41%
6 Month
-0.28%
-0.28%
1 Year
-59.63%
-59.63%

More News

Read More
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Adaptive Biotechnologies: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 14, 2024
Via Benzinga
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Earnings Preview For Adaptive Biotechnologies
Via Benzinga
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
Via Benzinga
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
From Adaptive Biotechnologies
Via GlobeNewswire
The 7 Best Penny Stocks to Buy in Q2 2024
Via InvestorPlace
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam
Via Benzinga
Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You?
Via The Motley Fool
Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails
Via Benzinga
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Invest Trims Bitcoin Exposure, Sells $2.9M Worth Of GBTC Shares Amid Crypto Market Volatility
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.